Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

[1]  J. Wedzicha,et al.  How Do Dual Long‐Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? , 2017, American journal of respiratory and critical care medicine.

[2]  C. Vogelmeier,et al.  Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study , 2016, European Respiratory Journal.

[3]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[4]  H. Magnussen,et al.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. , 2016, The Lancet. Respiratory medicine.

[5]  K. Kostikas,et al.  Does the Term “Deflators” Reflect More Accurately the Beneficial Effects of Long-acting Bronchodilators in COPD? , 2016 .

[6]  Nuofu Zhang,et al.  LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD , 2015, International journal of chronic obstructive pulmonary disease.

[7]  N. Horita,et al.  Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan , 2015, International journal of chronic obstructive pulmonary disease.

[8]  E. Bateman,et al.  Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study , 2014, BMC Pulmonary Medicine.

[9]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[10]  R. Fogel,et al.  Addressing unmet needs in the treatment of COPD , 2014, European Respiratory Review.

[11]  D. Niewoehner,et al.  Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study , 2014, Respiratory Research.

[12]  J. Bourbeau,et al.  The COPD assessment test: a systematic review , 2014, European Respiratory Journal.

[13]  E. Kerwin,et al.  Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[14]  D. Jadayel,et al.  Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. , 2014, Respiratory medicine.

[15]  N. Chavannes,et al.  Primary Care COPD Patients Compared with Large Pharmaceutically-Sponsored COPD Studies: An UNLOCK Validation Study , 2014, PloS one.

[16]  M. Decramer,et al.  Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study , 2013, European Respiratory Journal.

[17]  S. Kon,et al.  The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference , 2013, Thorax.

[18]  E. Bateman,et al.  Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.

[19]  E. Bateman,et al.  Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.

[20]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[21]  Pamela Berry,et al.  Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. , 2012, Chest.

[22]  J. Donohue,et al.  Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium , 2012, Respiratory Research.

[23]  H. Büller,et al.  External and internal validity of open label or double‐blind trials in oral anticoagulation: better, worse or just different? , 2011, Journal of thrombosis and haemostasis : JTH.

[24]  P. Kardos,et al.  Properties of the COPD assessment test in a cross-sectional European study , 2011, European Respiratory Journal.

[25]  W. Bailey,et al.  Disease severity and symptoms among patients receiving monotherapy for COPD. , 2010, Primary care respiratory journal : journal of the General Practice Airways Group.

[26]  R. Zuwallack,et al.  Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. , 2007, Chest.

[27]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[28]  D J Torgerson,et al.  Pragmatic trials: lab meets bedside , 2019, The British journal of dermatology.